An ongoing phase Ic randomized clinical trial (GC43343; https://forpatients.roche.com/en/trials/cardiovascular-disorder/coronary-artery-disease/a-phase-ic-multicenter--randomized--double-blind--placebo-contro.html) is studying the use of selnoflast, an NLRP3 inhibitor, in patients with coronary artery disease and elevated hsCRP with a substudy evaluating the specific effects in subjects with pathogenic TET2 variants. This evidence concerns the gene NLRP3 and coronary artery disorder.